Categories Concall Highlights, Earnings, Health Care

Aurobindo Pharma Limited Q2 FY24 Earnings Conference Call Insights

Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q2 FY24 Earnings Concall

  • Revenue Growth
    • Revenue grew 25.8% year-on-year to INR7,219 crores, driven by growth across formulations, APIs, and geographies.
    • Formulations revenue, excluding Puerto Rico, grew 29% YoY to INR5,968 crores.
    • US formulations revenue, without Puerto Rico, grew 35.7% year-on-year to INR3,385 crores, driven by volume gains, stable demand and new launches.
    • Europe formulations revenue grew 16.7% year-on-year to INR1,769 crores.
    • Growth markets revenue grew 24.7% year-on-year to INR564 crores.
  • Margin Expansion
    • EBITDA grew 67.7% year-on-year and 21.9% quarter-on-quarter to INR1,403 crores.
    • EBITDA margin expanded to 19.4% against 16.8% last quarter.
    • Margin expansion driven by higher capacity utilization, operating leverage, lower material costs, and favorable product mix.
  • US Business Performance
    • Received 15 ANDA approvals and launched 19 products in Q2 FY24.
    • Filed 10 ANDAs during the quarter.
    • US revenue growth driven by injectables and oral solids.
    • Improved pricing environment in US with price erosion remaining neutral.
    • US formulations revenue excluding Puerto Rico grew 35.7% year-on-year.
    • Injectables revenue stabilized around $80-90 million per quarter currently.
    • Oral solids growing at double digit rate driven by new product launches and volume gains.
    • Launching 40 new products in 12 months, on track.
    • Leveraging manufacturing capabilities and broad portfolio
  • Capacity Expansion
    • Multiple manufacturing plants under installation and commissioning.
    • New plants in China, Pen G, and API expected to be operational starting Q4 FY24.
    • Clinical trials underway for biosimilars plant which will be commissioned in FY25/26.
    • Existing plants undergoing debottlenecking to increase capacity.
  • Outlook
    • Confident of sustaining growth momentum in revenue and earnings.
    • Expect to achieve over 20% EBITDA margin target for FY24.
    • Focus on new product launches, cost efficiencies and expanding product pipeline.
    • Exploring bolt-on acquisitions aligned with company’s growth strategy.
    • Targeting over 20% EBITDA margin for FY24.
    • R&D spend expected to increase back to INR350-400 crores per quarter.
    • With plants getting commissioned, capex may moderate from FY25.
    • Strategy capex of $100-150 million will continue for biosimilars, CMO etc.
    • Existing generics business may not require major capex.
  • MSD Partnership
    • Signed letter of intent to partner with MSD for biologics contract manufacturing.
    • Will invest in infrastructure for innovator biologics manufacturing with capacity of over 15 KL bioreactors.
    • Aims to compete with major CMOs globally in both drug substance and finished product.
    • Final investment amount still under negotiation, expected clarity in 4-5 months.
  • Debt Position
    • Gross debt increased by $160 million in Q2 FY24.
    • Spent on Indonesia acquisition, PLA plant capex, working capital.
    • Expect to end FY24 with net debt between $0-50 million.
    • Cash flows from PLA plant will help reduce net debt next fiscal year.
  • Revlimid Launch
    • Launched in October 2023.
    • Pricing similar to competitors.
    • Planning for stable quarterly revenue contribution throughout settlement period.
  • Europe Business Outlook
    • Focus on improving profitability and margins rather than chasing top line growth.
    • Aiming to achieve company average EBITDA margins of 20% with scale.
    • New injectable and biosimilar launches to aid growth along with China facility.
  • Indonesia Acquisition
    • Acquired Pfizer’s branded portfolio in Indonesia.
    • 16 well-known brands with INR31 million revenue.
    • Gives direct presence in large and growing pharma market.
    • Closed in Q3 FY24, will aid growth from FY25.
  • Europe Biosimilar Filings
    • Faced delay earlier, have resubmitted Pegfilgrastim file.
    • Will submit Filgrastim and Trastuzumab files by end of January 2024.
    • Pegfilgrastim and Filgrastim approvals expected in FY26.
    • Trastuzumab approval likely in FY27.
    • Audit for Filgrastim expected in Q1 2024.
  • ARV Business Revenue
    • Quarterly revenue around $25 million ± $5 million.
    • No huge growth expected unless unable to supply in a quarter.
  • Organic Capex
    • Existing plants capex around $125-150 million annually.
    • Not embarking on major new greenfield plants currently.
    • Adding lines and debottlenecking existing plants to reduce gestation period.
  • Inorganic Investments
    • Spent $95 million this year on acquisitions for new markets and business.
    • Do not foresee similar scale of investments every year.
    • Will evaluate bolt-on acquisitions if value-accretive opportunities arise.

Most Popular

Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript

Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah

All you need to know about Antony Waste Handling Cell in one article

Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?

Demystifying the Leading Non-Ferrous Recycling Company of India

“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,